Search

Your search keyword '"T, Borsos"' showing total 71 results

Search Constraints

Start Over You searched for: Author "T, Borsos" Remove constraint Author: "T, Borsos" Journal journal of immunology baltimore md 1950 Remove constraint Journal: journal of immunology baltimore md 1950
71 results on '"T, Borsos"'

Search Results

1. Biosynthesis of the second and fourth components of complement: inhibition in vitro by chemical carcinogens.

2. Metabolic requirements for hormone-induced resistance to antibody-complement mediated killing of tumor cells.

3. Hemolytic efficiency of cell-bound IgM: evidence that IgM-C1 complexes activate C4 molecules not hemolytic with homologous C2--C9.

4. Studies on the terminal stages of immune hemolysis. IV. Effect of metal salts.

5. Studies on the terminal stages of antibody-complement-mediated killing of a tumor cell. I. Evidence for the existence of an intermediate, T.

6. Differences in cell-bound C8 sites on chicken erythrocytes measured by their reactivity with guinea pig and human C9.

7. Binding and activation of hemolytic complement by IgG antibodies: cooperativity between antibodies of different hapten specificity.

8. Complement inhibitor(s) released by leukocytes. I. Pretreatment of sheep erythrocytes with supernatants of mouse spleen and thymus cells inhibit whole complement activity and C2 utilization.

10. Studies on the interaction between protein A and immunoglobulin G. I. Effect of protein A on the functional activity of IgG.

11. Studies on the terminal stages of immune hemolysis. V. Evidence that not all complement-produced transmembrane channels are equal.

12. Effect of concanavalin A on the killing of tumor cells by antibody and complement.

13. Lysis of hapten-labeled cells by anti-hapten IgG and complement: effect of cell surface hapten density.

14. Correlation between the ability of tumor cells to resist humoral immune attack and their ability to synthesize lipid.

15. Activation of human C1r: Western blot analysis reveals slow and dose-dependent activation.

16. Studies on the terminal stages of immune hemolysis. VI. Osmotic blockers of differing Stokes' radii detect complement-induced transmembrane channels of differing size.

17. Lysis of tumor cells by antibody and complement. II. Lack of correlation between amount of C4 and C3 fixed and cell lysis.

18. Identification of lipids synthesized and released by tumor cells under attack by antibody and complement.

19. Cell-bound C4b resists reduction by reducing agents: analysis by chain structure and by hemolytic activity.

20. Quantitative comparison of techniques used to measure complement-mediated cytotoxicity of nucleated cells.

21. Distinction between C8-mediated and C8/C9-mediated hemolysis on the basis of independent 86Rb and hemoglobin release.

22. Immunochemical quantitaion of the third component of guinea pig complement in fluid phase and bound to cell surfaces.

23. Studies on the terminal stages of antibody-complement mediated killing of a tumor cell. III. Effect of membrane active agents.

24. Anti-hapten IgG antibodies bound to cell surface hapten: anti-IgG antibody prevents dissociation as measured with fluid phase hapten.

25. Lysis of tumor cells by antibody and complement. VII. Complement-dependent 86Rb release--a nonlethal event?

26. Immunochemical quantitation of cell bound C4.

27. Activation of human C1: analysis with Western blotting reveals slow self-activation.

29. Antigenic relationship between the fourth component of human and guinea pig complement.

30. Identification of lipids associated with the ability of tumor cells to resist humoral immune attack.

31. Stimulation of the synthesis and release of lipids in tumor cells under attack by antibody and C.

32. Effect of concanavalin A on the classical complement pathway.

33. Studies on the terminal stages of immune hemolysis. III. Distinction between the insertion of C9 and the formation of a transmembrane channel.

34. Lysis of tumor cells by antibody and complement. III. Lack of correlation between antigen movement and cell lysis.

35. Studies on the terminal stages of antibody-complement-mediated killing of a tumor cell. II. Inhibition of transformation of T to dead cells by 3'5' cAMP.

36. Synthesis of specific lipids associated with the hormone-induced resistance of tumor cells to humoral immune killing.

37. C4 does not bind to human and rabbit IgM during activation of the classical complement pathway on the red cell.

39. Lysis of tumor cells by antibody and complement. VI. Enhanced killing of enzyme-pretreated tumor cells.

40. Naturally soluble tumor antigens from guinea pig hepatomas: isolation and partial characterization.

42. Immune hemolysis and the functional properties of the second (C2) and fourth (C4) components of complement. I. Functional differences among C4 sites on cell surfaces.

Catalog

Books, media, physical & digital resources